Hepatitis B Articles (HBV)
Back
	TAF / HBV / Resistance       AASLD: Reduced Changes in Bone Mineral Density in Chronic HBV (CHB) Patients Receiving Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) - (11/22/16)   AASLD: Comparison of Markers of Bone Turnover Demonstrates Less Changes in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)   AASLD: Improved Renal Laboratory Parameters in CHB Patients Treated With TAF Compared With TDF - (11/22/16)   AASLD: Minimal Changes in Urine Markers of Tubular Dysfunction in CHB Patients Receiving Tenofovir Alafenamide Compared With Tenofovir Disoproxil Fumarate - (11/22/16)   AASLD: No Resistance to Tenofovir Alafenamide Detected Through 48 Weeks of Treatment in Patients With Chronic Hepatitis B - (11/22/16)   AASLD: Characterization of Changes in FibroTest Values During Treatment With TAF or TDF in Patients With CHB - (11/22/16)   AASLD: Characterization of Host, Viral, and Treatment-Related Factors Associated With Antiviral Efficacy of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate - (11/22/16)   AASLD: HBV Genotype Is Associated With Early (Week 12) Virologic Response During Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Therapy in Patients With Chronic Hepatitis B - (11/22/16)   ----------------------------   HIV Dart/2016: Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V - (12/15/16)   Antiviral Activity of Tenofovir Alafenamide (TAF) against Major NRTI-Resistant Viruses: Improvement over TDF/TFV is Driven by Higher TFV-DP Loading in Target cells (06/09/13)           View Older Articles   Back to Top   www.natap.org